Men's gallbladder cancer: epidemiology, prevention, and treatment strategies

Herein, it was aimed to review the epidemiology, prevention, and treatment strategies for men’s gallbladder cancer (GBC). “Gallbladder cancer” and “GBC” were searched in four online databases (PubMed, ScienceDirect, Scopus and Google Scholar). Six from 987 articles were selected after inclusion and exclusion processes. Data were collected online from all the studies. It was confirmed that GBC began with the weight control through glucagon-like peptide 1 (GLP-1), type 2 diabetes treatment, or healthy diet. GBC treatment strategies included surgery, chemotherapy and targeted therapies. New oral agents such as varlitinib, capecitabine, trifluridine/tripiracil (FTD/TPI), and pemigatinib with olaparib were employed as the second-line treatment for GBC. Understanding the epidemiology, prevention, and treatment strategies regarding GBC could minimize its negative prognosis and provide support for developing new therapies in future. Despite the continuous advancements pertaining to cancers, studies had been lacking on GBC. More information on GBC regarding prevention and treatment strategies would improve its handling.

Gallbladder cancer; Epidemiology; Prevention; Treatment strategies

[1] Sun Y, Li X, Cheng H, Wang S, Zhou D, Ding J, et al. Drug resistance and new therapies in gallbladder cancer. Drug Discoveries & Therapeutics. 2023; 17: 220–229.

[2] Roa JC, García P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nature Reviews Disease Primers. 2022; 8: 69.

[3] Dutta A, Mungle T, Chowdhury N, Banerjee P, Gehani A, Sen S, et al. Characteristics and outcomes of gallbladder cancer patients at the Tata Medical Center, Kolkata 2017–2019. Cancer Medicine. 2023; 12: 9293–9302.

[4] Wang S, Zheng R, Li J, Zeng H, Li L, Chen R, et al. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN. The Lancet Gastroenterology & Hepatology. 2024; 9: 229–237.

[5] Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clinical epidemiology. 2014; 6: 99–109.

[6] Pérez-Moreno P, Riquelme I, García P, Brebi P, Roa JC. Environmental and lifestyle risk factors in the carcinogenesis of gallbladder cancer. Journal of Personalized Medicine. 2022; 12: 234.

[7] Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut and Liver. 2012; 6: 172–187.

[8] Xie ZH, Shi X, Liu MQ, Wang J, Yu Y, Zhang JX, et al. Development and validation of a nomogram to predict overall survival in patients with incidental gallbladder cancer: a retrospective cohort study. Frontiers in Oncology. 2023; 12: 1007374.

[9] Katru P, Sharma R, Porte S, Sharma A. An overview of Gulma and its relation to gallbladder cancer. International Journal of Innovative Science Research Technology. 2023; 8: 516–521.

[10] Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology. 2019; 20: 663–673.

[11] Fang C, Li W, Wang Q, Wang R, Dong H, Chen J, et al. Risk factors and prognosis of liver metastasis in gallbladder cancer patients: a SEER-based study. Frontiers in Surgery. 2022; 9: 899896.

[12] He S, Yu TN, Cao JS, Zhou XY, Chen ZH, Jiang WB, Cai LX, Liang X. Laparoscopic vs open radical resection in management of gallbladder carcinoma: a systematic review and meta-analysis. World Journal of Clinical Cases. 2023; 11: 6455–6475.

[13] Zhou Y, Yuan K, Yang Y, Ji Z, Zhou D, Ouyang J, et al. Gallbladder cancer: current and future treatment options. Frontiers in Pharmacology. 2023; 14: 1183619.

[14] Li M, Xie X, Xu H, Li H. A psychological nursing intervention for patients with breast cancer on inflammatory factors, negative emotions and quality of life. Iranian Journal of Public Health. 2022; 51: 2041–2047.

[15] Gupta S, Kori C, Kumar V, Misra S, Akhtar N. Epidemiological study of gallbladder cancer patients from north Indian Gangetic planes—a high-volume centre’s experience. Journal of Gastrointestinal Cancer. 2016; 47: 27–35.

[16] Schmidt MA, Marcano-Bonilla L, Roberts LR. Gallbladder cancer: epidemiology and genetic risk associations. Chinese Clinical Oncology. 2019; 8: 31.

[17] Halaseh SA, Halaseh S, Shakman R. A review of the etiology and epidemiology of gallbladder cancer: what you need to know. Cureus. 2022; 14: e28260.

[18] Xu Y, Abdelazeem B, Abbas KS, Lin Y, Wu H, Zhou F, et al. Non-cancer causes of death following initial synchronous bone metastasis in cancer patients. Frontiers in Medicine. 2022; 9: 899544.

[19] Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clinical and Experimental Hepatology. 2019; 5: 93–102.

[20] Chouhan A. An epidemiological prospective study on the relation between gallbladder cancer and gall stones disease. European Journal of Cardiovascular Medicine. 2023; 13: 250–256.

[21] Singh D, Singh P, Mandal A, Rakesh A. Prognostic insights and survival analysis of gallbladder cancer in Bihar, India: a prospective observational study emphasizing the impact of surgical intervention on overall survival. To be published in Indian Journal of Surgical Oncology. 2024. [Preprint].

[22] Jackson SS, Marks MA, Katki HA, Cook MB, Hyun N, Freedman ND, et al. Sex disparities in the incidence of 21 cancer types: quantification of the contribution of risk factors. Cancer. 2022; 128: 3531–3540.

[23] Zhang Y, Zhou T, Han S, Chang J, Jiang W, Wang Z, et al. Development and external validation of a nomogram for predicting the effect of tumor size on cancer-specific survival of resected gallbladder cancer: a population-based study. International Journal of Clinical Oncology. 2021; 26: 1120–1129.

[24] Yan Y, Lin J, Zhang M, Liu H, Zhou Q, Chen R, et al. A novel staging system to forecast the cancer-specific survival of patients with resected gallbladder cancer. Frontiers in Oncology. 2020; 10: 1281.

[25] Zhu J, Wu Y, Xiao W, Li Y. Survival predictors of resectable gallbladder carcinoma: an analysis of the surveillance, epidemiology, and end results database. The American Surgeon. 2023; 89: 1629–1637.

[26] Zhou H, Chen J, Jin H, Liu K. Genetic characteristics and clinical-specific survival prediction in elderly patients with gallbladder cancer: a genetic and population-based study. Frontiers in Endocrinology. 2023; 14: 1159235.

[27] Xu X, He M, Wang H, Zhan M, Yang L. Development and validation of a prognostic nomogram for gallbladder cancer patients after surgery. BMC Gastroenterology. 2022; 22: 200.

[28] Cowzer D, Harding JJ. Advanced bile duct cancers: a focused review on current and emerging systemic treatments. Cancers. 2022; 14: 1800.

[29] Kamarajah SK, Al-Rawashdeh W, White SA, Abu Hilal M, Salti GI, Dahdaleh FS. Adjuvant radiotherapy improves long-term survival after resection for gallbladder cancer a population-based cohort study. European Journal of Surgical Oncology. 2022; 48: 425–434.

[30] Sahara K, Tsilimigras DI, Kikuchi Y, Ethun CG, Maithel SK, Abbott DE, et al. Defining and predicting early recurrence after resection for gallbladder cancer. Annals of Surgical Oncology. 2021; 28: 417–425.

[31] Liu R, Qiu Z, Zhang L, Ma W, Zi L, Wang K, et al. High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers. Journal of Cachexia, Sarcopenia and Muscle. 2023; 14: 2509–2519.

[32] Isanejad M, Steffen LM, Terry JG, Shikany JM, Zhou X, So‐YunYi, et al. Diet quality is associated with adipose tissue and muscle mass: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Journal of Cachexia, Sarcopenia and Muscle. 2024; 15: 425–433.

[33] Wilson RB, Lathigara D, Kaushal D. Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk. International Journal of Molecular Sciences. 2023; 24: 6192.

[34] Di Carlo P, Serra N, Alduina R, Guarino R, Craxì A, Giammanco A, et al. A systematic review on omics data (metagenomics, metatranscriptomics, and metabolomics) in the role of microbiome in gallbladder disease. Frontiers in Physiology. 2022; 13: 888233.

[35] Chen Y, Shen X, Ma T, Yu X, Kwok L, Li Y, et al. Adjunctive probio-X treatment enhances the therapeutic effect of a conventional drug in managing Type 2 diabetes mellitus by promoting short-chain fatty acid-producing bacteria and bile acid pathways. mSystems. 2023; 8: e0130022.

[36] Zhang L, Chu J, Hao W, Zhang J, Li H, Yang C, Yang J, Chen X, Wang H. Gut microbiota and type 2 diabetes mellitus: association, mechanism, and translational applications. Mediators of Inflammation. 2021; 2021: 5110276.

[37] Zhai L, Wu J, Lam YY, Kwan HY, Bian ZX, Wong HLX. Gut-microbial metabolites, probiotics and their roles in type 2 diabetes. International Journal of Molecular Sciences. 2021; 22: 12846.

[38] Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023; 330: 1795.

[39] Latif W, Lambrinos KJ, Patel P, Rodriguez R. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). StatPearls Publishing: Treasure Island (FL). 2024.

[40] Simon TG, Patorno E, Schneeweiss S. Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes. Clinical Gastroenterology and Hepatology. 2022; 20: 1382–1393.e19.

[41] Chen S, Chuang Y, Lin T, Yang J. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases. European Journal of Pharmacology. 2023; 938: 175439.

[42] Amisha F, Malik P, Saluja P, Gautam N, Patel TH, Roy AM, et al. A comprehensive review on the role of human epidermal growth factor receptor 2 (HER2) as a biomarker in extra-mammary and extra-gastric cancers. Onco. 2023; 3: 96–124.

[43] Achalla LSV, Shinde RK, Jogdand S, Vodithala S. Review of the role of HER2/neu in colorectal carcinomas. Cureus. 2022; 14: e25409.

[44] Joris S, Denys H, Collignon J, Rasschaert M, T’Kint de Roodenbeke D, Duhoux FP, et al. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. ESMO Open. 2023; 8: 102041.

[45] Szentmartoni G, Mühl D, Csanda R, Szasz AM, Herold Z, Dank M. Predictive value and therapeutic significance of somatic BRCA mutation in solid tumors. Biomedicines. 2024; 12: 593.

[46] Ekram SN, Al Shanbari N, Bin Laswad BM, Alharthi A, Tayeb W, Bahha A. Checkpoint kinase 2 (CHEK2) gene mutation in a patient with breast and prostate cancer: a unique presentation of a rare disease. Cureus. 2023; 15: e49710.

[47] Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Journal of Clinical Oncology. 2023; 41: 1703–1713.

[48] Germani A, Petrucci S, De Marchis L, Libi F, Savio C, Amanti C, et al. Beyond BRCA1 and BRCA2: deleterious variants in DNA repair pathway genes in italian families with breast/ovarian and pancreatic cancers. Journal of Clinical Medicine. 2020; 9: 3003.

[49] Sturm N, Schuhbaur JS, Hüttner F, Perkhofer L, Ettrich TJ. Gallbladder cancer: current multimodality treatment concepts and future directions. Cancers. 2022; 14: 5580.

[50] Sturm N, Schuhbaur JS, Hüttner F, Perkhofer L, Ettrich TJ. Gallbladder cancer: current multimodality treatment concepts and future directions. Cancers. 2022; 14: 5580.

[51] Okumura K, Gogna S, Gachabayov M, Felsenreich DM, McGuirk M, Rojas A, et al. Gallbladder cancer: Historical treatment and new management options. World Journal of Gastrointestinal Oncology. 2021; 13: 1317–1335.

[52] Joris S, Denys H, Collignon J, Rasschaert M, T’Kint de Roodenbeke D, Duhoux FP, et al. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian precision tumor-agnostic phase II study. ESMO Open. 2023; 8: 102041.

[53] Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. 2023; 401: 195–203.

[54] Javle MM, Oh DY, Ikeda M, Yong WP, Hsu K, Lindmark B, et al. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp). ESMO Open. 2022; 7: 100314.

[55] Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers. 2020; 12: 2039.

[56] Vignone A, Biancaniello F, Casadio M, Pesci L, Cardinale V, Ridola L, Alvaro D. Emerging therapies for advanced cholangiocarcinoma: an updated literature review. Journal of Clinical Medicine. 2021; 10: 4901.

[57] Sun Y, Li X, Cheng H, Wang S, Zhou D, Ding J, et al. Drug resistance and new therapies in gallbladder cancer. Drug Discoveries & Therapeutics. 2023; 17: 220–229.

[58] Oh MY, Kim H, Choi YJ, Byun Y, Han Y, Kang JS, et al. Conversion surgery for initially unresectable extrahepatic biliary tract cancer. Annals of Hepato-Biliary-Pancreatic Surgery. 2021; 25: 349–357.

[59] Thavaneswaran S, Kansara M, Lin F, Espinoza D, Grady JP, Lee CK, et al. A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. British Journal of Cancer. 2023; 129: 475–485.

[60] Kehmann L, Berres ML, Gonzalez-Carmona M, Modest DP, Mohr R, Wree A, et al. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC). BMC Cancer. 2023; 23: 470.

[61] Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1–3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Annals of Oncology. 2022; 33: 522–533.